Details of the Drug

General Information of Drug (ID: DM14MAE)

Drug Name
Pergolide
Synonyms
Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Approved [1]
Therapeutic Class
Antiparkinson Agents
Affected Organisms
Humans and other mammals
ATC Code
N04BC02: Pergolide
N04BC: Dopamine agonists
N04B: DOPAMINERGIC AGENTS
N04: ANTI-PARKINSON DRUGS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 314.5
Logarithm of the Partition Coefficient (xlogp) 4.2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C19H26N2S
IUPAC Name
(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
Canonical SMILES
CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
InChI
InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
InChIKey
YEHCICAEULNIGD-MZMPZRCHSA-N
Cross-matching ID
PubChem CID
47811
ChEBI ID
CHEMBL531
CAS Number
66104-22-1
UNII
24MJ822NZ9
DrugBank ID
DB01186
TTD ID
D04JCN
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Modulator [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D1 receptor (D1R) DTT DRD1 8.99E-01 -0.06 -0.3
Dopamine D2 receptor (D2R) DTT DRD2 2.20E-03 -0.51 -1.35
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pergolide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
OPC-34712 DMHG57U Moderate Antagonize the effect of Pergolide when combined with OPC-34712. Depression [6A70-6A7Z] [3]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Pergolide and Esketamine. Depression [6A70-6A7Z] [4]
ITI-007 DMUQ1DO Moderate Antagonize the effect of Pergolide when combined with ITI-007. Insomnia [7A00-7A0Z] [3]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Pergolide and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [5]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Pergolide and Lasmiditan. Migraine [8A80] [6]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Pergolide and Flibanserin. Mood disorder [6A60-6E23] [7]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Pergolide when combined with Metoclopramide. Nausea/vomiting [MD90] [3]
Levomepromazine DMIKFEL Moderate Additive CNS depression effects by the combination of Pergolide and Levomepromazine. Psychotic disorder [6A20-6A25] [3]
Quetiapine DM1N62C Moderate Antagonize the effect of Pergolide when combined with Quetiapine. Schizophrenia [6A20] [3]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Pergolide when combined with Aripiprazole. Schizophrenia [6A20] [3]
Iloperidone DM6AUFY Moderate Antagonize the effect of Pergolide when combined with Iloperidone. Schizophrenia [6A20] [3]
Paliperidone DM7NPJS Moderate Antagonize the effect of Pergolide when combined with Paliperidone. Schizophrenia [6A20] [3]
Molindone DMAH70G Moderate Antagonize the effect of Pergolide when combined with Molindone. Schizophrenia [6A20] [3]
Thiothixene DMDINC4 Moderate Antagonize the effect of Pergolide when combined with Thiothixene. Schizophrenia [6A20] [3]
Amisulpride DMSJVAM Major Additive CNS depression effects by the combination of Pergolide and Amisulpride. Schizophrenia [6A20] [4]
Asenapine DMSQZE2 Moderate Antagonize the effect of Pergolide when combined with Asenapine. Schizophrenia [6A20] [3]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Pergolide when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [8]
⏷ Show the Full List of 17 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 48).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
4 Cerner Multum, Inc. "Australian Product Information.".
5 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
6 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
7 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
8 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.